Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Milo Gatti & Federico Pea. (2023) The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan. Expert Review of Clinical Pharmacology 16:11, pages 1035-1051.
Read now
Read now
Milo Gatti & Federico Pea. (2023) Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert Review of Anti-infective Therapy 21:2, pages 149-166.
Read now
Read now
Articles from other publishers (5)
German V. Kukushkin, Marina V. Zhuravleva & Dmitry E. Yurov. (2023) Influence of drugs with hyaluronidase activity on the survival of animals with a purulent-inflammatory process in the abdominal organs. Medical Journal of the Russian Federation 29:2, pages 99-105.
Crossref
Crossref
Keith S. Kaye, Thierry Naas, Jason M. Pogue & Gian Maria Rossolini. (2023) Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales. Infectious Diseases and Therapy 12:3, pages 777-806.
Crossref
Crossref
Massimo Sartelli, Francesco Cristini, Federico Coccolini, Francesco Maria Labricciosa, Walter Siquini & Fausto Catena. (2022) A Proposal for a Classification Guiding the Selection of Appropriate Antibiotic Therapy for Intra-Abdominal Infections. Antibiotics 11:10, pages 1394.
Crossref
Crossref
Lidia DALFINO & Salvatore GRASSO. (2022) Personalized antimicrobial policies in severe peritonitis: opportunities not to be missed!. Minerva Anestesiologica 88:5.
Crossref
Crossref
Pier Giorgio Cojutti, Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, Cristiana Laici, Chiara Mega, Antonio Siniscalchi, Maddalena Giannella, Pierluigi Viale & Federico Pea. (2021) Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Frontiers in Pharmacology 12.
Crossref
Crossref